Dossier - 07/02/2011 The era of personalised medicine is dawning A promising future does not easily disappear into thin air. This is certainly the case with the vision of personalised medicine. For many years, biomedical researchers have vaunted the potential benefits of their findings despite the fact that neutral observers do not think that personalised medicine will really take off within the next 15 or 20 years. Moreover personalised medicine is a controversial term. So what is the state of play right now?https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-era-of-personalised-medicine-is-dawning
Article - 09/09/2013 The Heinrich-Lanz Centre for Personalised Medicine in Mannheim A Centre for Translational Research and Personalised Medicine is currently emerging at the Faculty of Medicine in Mannheim, University of Heidelberg. The new centre is expected to boost the development of new therapies in cooperation with partners from Germany and abroad. The centre also works closely with the “French-German Advanced Translational Drug Discovery Center”, a unique, large-scale, cross-border research cooperation between French and…https://www.gesundheitsindustrie-bw.de/en/article/news/the-heinrich-lanz-centre-for-personalised-medicine-in-mannheim
Press release - 15/02/2011 Cellzome Announces Achievement of Second Milestone in Epigenetics Collaboration with GSK Cellzome announced today that it has achieved the second milestone in its epigenetics alliance with GlaxoSmithKline. The milestone triggers a payment of an undisclosed amount from GSK and follows only two months after the first milestone was achieved. https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellzome-announces-achievement-of-second-milestone-in-epigenetics-collaboration-with-gsk
Article - 14/02/2011 Comprehensive data analysis as the basis for individualised drugs Individual patients metabolise certain drugs in very different ways some patients metabolise drugs well and others do not respond at all. The difference in individual patients ability to metabolise drugs depends not only on environmental influences but also on genetic factors which means that the sequencing of the human genome has become a major prerequisite for the application of personalised medicine. In the following interview Dr. Jens…https://www.gesundheitsindustrie-bw.de/en/article/news/comprehensive-data-analysis-as-the-basis-for-individualised-drugs
Article - 13/11/2010 Evidence in personalised medicine Personalised medicine is the potential capacity to systematically use information about an individual patient in order to select or optimise that patient’s therapeutic care and tailor individual preventive treatments. Biomarkers need to be used as objective parameters in order to determine a patient’s individual risk profile. The role that features detected by genetic tests play in the causal mechanism of diseases and whether they are suitable…https://www.gesundheitsindustrie-bw.de/en/article/news/evidence-in-personalised-medicine
Article - 25/06/2012 From blood samples to granulate The issue of proper nutrition has become more centred on the individual there is growing recognition that nutrition needs to be adapted to an individuals specific way of life and requirements. In cooperation with its subsidiary the Institut für Angewandte Biochemie AG IABC Hepart AG a company based in the city of Kreuzlingen on Lake Constance develops dietary products food to help people lose weight and micronutrient preparations adapted to…https://www.gesundheitsindustrie-bw.de/en/article/news/from-blood-samples-to-granulate
Article - 29/11/2010 CYP2D6 and the oestrogen receptor The medicinal adjuvant therapy of breast cancer is a good example of how important it is being aware that different patients metabolise drugs differently. This knowledge plays a key role in the prescription of effective drugs at the correct dose and in preventing adverse reactions and interactions with concomitant drugs.https://www.gesundheitsindustrie-bw.de/en/article/news/cyp2d6-and-the-oestrogen-receptor
Article - 08/11/2010 Individual genome sequencing – for whom? Next-generation sequencing technologies are fast and effective. This is exactly the reason why the International Cancer Genome Consortium, of which the German Cancer Research Center is part, has set itself the goal of sequencing thousands of individual cancer genomes. Private companies also offer the possibility of sequencing genomes for private clients. It looks as if the problematic vision of “googling your genes” might become reality.https://www.gesundheitsindustrie-bw.de/en/article/news/individual-genome-sequencing-for-whom
Article - 30/08/2010 Genetic testing for the prevention of diseases? Genetic testing is beginning to play an important role in personalised medicine and is indispensable for the diagnosis and therapy of many diseases. However, the preventive and diagnostic power of many genetic tests is still inferior to traditional diagnostic tests. In addition, commercial genetic tests do not always live up to the claims made about them. https://www.gesundheitsindustrie-bw.de/en/article/news/genetic-testing-for-the-prevention-of-diseases
Press release - 18/09/2009 Why don’t brain tumours respond to drugs? Malignant brain tumours do not often respond to promising new drugs. Researchers from Heidelberg have now uncovered a mechanism and a tumour marker that are linked to the development of this resistance. A “death receptor” might possibly indicate the chances of success of chemotherapy at the same time as providing new approaches for developing a new therapy for the successful treatment of brain tumours.https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-don-t-brain-tumours-respond-to-drugs
Article - 07/02/2011 The discovery of the individual as business model The move towards personalised medicine has made considerable progress, in particular in the field of oncology, where it is leading to the close integration of diagnostics and therapy as well as to the development of profitable new business models, some of which have controversial exclusive legal claims.https://www.gesundheitsindustrie-bw.de/en/article/news/the-discovery-of-the-individual-as-business-model
Lab-on-a-chip - 11/11/2020 Microfluidic platform for the best possible cancer therapy Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.https://www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
Article - 27/01/2014 immatics biotechnologies GmbH: active against cancer immatics biotechnologies GmbH is a biopharmaceutical company wholly concerned with the development of advanced immunotherapies that are active against different types of cancer, including renal cell, colorectal, brain and gastric cancer. The company currently has a workforce of 80 at its headquarters in Tübingen and subsidiary in Munich. It capitalises on the know-how in the analysis of tumour cells and vaccine development gained through its…https://www.gesundheitsindustrie-bw.de/en/article/news/immatics-biotechnologies-gmbh-active-against-cancer
Article - 31/03/2014 TherapySelect – Identifying Susceptibility to Cancer Therapy TherapySelect Dr. Frank Kischkel is an innovative biotechnology company based in Heidelberg, Germany, with a special focus on the development, validation and application of diagnostic tests for cancer patients. The company’s proprietary CTR-Test® uses patients’ cancer cells to determine the tumor’s susceptibility to treatment with cytostatic drugs. This knowledge helps identify ineffective drugs prior to treatment as well as reduce adverse drug…https://www.gesundheitsindustrie-bw.de/en/article/news/therapyselect-identifying-susceptibility-to-cancer-therapy
Press release - 07/03/2015 Genome Analysis of Cancer Cells: Germany’s Biggest Sequencing Unit Established in Heidelberg Thorough examination of the genome of cancer cells is essential for a better understanding of the disease and to improve treatment. Therefore, the German Cancer Research Center (DKFZ), with the support of the German Cancer Consortium (DKTK), will invest in the Illumina HiSeq X Ten Sequencing System, the world’s first and only platform to deliver full coverage human whole genome for less than 1000 Euros per genome with the power to sequence more…https://www.gesundheitsindustrie-bw.de/en/article/press-release/genome-analysis-of-cancer-cells-germany-s-biggest-sequencing-unit-established-in-heidelberg
Article - 12/08/2013 A complete exome sequence in one week The exome is the part of the genome that is formed by exons i.e. the DNA regions that code for proteins and other functional products. Though comprising only about 1 of the total genome the majority of disease-causing mutations occur in the exome. Selectively sequencing the coding regions of the genome is quicker than whole-genome sequencing. Therefore exome sequencing plays an important role in the diagnosis of genetic diseases and cancer.…https://www.gesundheitsindustrie-bw.de/en/article/news/a-complete-exome-sequence-in-one-week
Article - 04/02/2013 DKFZ-HIPO – the Heidelberg Center for Personalised Oncology The German Cancer Research Center (DKFZ) and the National Center for Tumour Diseases (NCT) have jointly initiated the Heidelberg Center for Personalised Oncology (HIPO) which provides cancer patients with high-throughput genetic and molecular analyses. In anticipation of the upcoming World Cancer Day on 4th February 2013, the potential of high-throughput genetic and molecular analyses in improving cancer therapy was presented at a workshop held…https://www.gesundheitsindustrie-bw.de/en/article/news/dkfz-hipo-the-heidelberg-center-for-personalised-oncology
Article - 09/03/2015 Treating cancer by activating the immune system Vaccines that prevent infection with cancer-causing viruses are already available. Moreover, the development of therapeutic vaccines for the treatment of a number of other cancers is well under way. These vaccines not only prevent the development of cancer, but also treat early stages of cancer. Antigen-armed antibodies have long been used in vaccines against infectious diseases, and can now also be used for treating cancer. https://www.gesundheitsindustrie-bw.de/en/article/news/treating-cancer-by-activating-the-immune-system
Article - 27/06/2011 The EURAT project at the Marsilius Kolleg in Heidelberg Bioinformaticians, human geneticists, molecular biologists, oncologists, pathologists, lawyers and theologians are all participating in the project “Ethical and legal aspects of the total sequencing of the human genome” (EURAT) being carried out at Heidelberg University’s Marsilius Kolleg. The project partners are developing a common viewpoint and working out solutions for problems arising from the possibilities of total genome sequencing. https://www.gesundheitsindustrie-bw.de/en/article/news/the-eurat-project-at-the-marsilius-kolleg-in-heidelberg
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Press release - 09/11/2020 European TRIANKLE project will develop 3D bioprinted personalised scaffolds for tissue regeneration of ankle joint The Research consortium is composed of 12 partners from 5 European countries and counts with a EU funding of €5.9M. TRIANKLE will provide fabrication of personalized implants for injured tendons or cartilages. Fraunhofer IGB will formulate and develop collagen- and gelatine-based bio-inks needed for 3D printing the personalised implants.https://www.gesundheitsindustrie-bw.de/en/article/press-release/european-triankle-project-will-develop-3d-bioprinted-personalised-scaffolds-tissue-regeneration-ankle-joint
Digitalisation in Medicine - 08/12/2020 DiHeSys takes steps towards application Digital Health Systems GmbH (DiHeSys) has completed its founding phase and entered a new stage of development. This is reflected in the arrival of a new managing director, a strategic cooperation and its first pilot projects.https://www.gesundheitsindustrie-bw.de/en/article/news/dihesys-takes-steps-towards-application
Article - 09/01/2012 Biomarkers to combat lung cancer A biomarker-driven personalised therapeutic approach to lung cancer is possible – this is the conclusion reached by the BATTLE trial. The preliminary results of the trial were summarised by scientists from the Thoraxklinik at Heidelberg University Hospital in the May 2011 issue of “Clinical Investigation”.https://www.gesundheitsindustrie-bw.de/en/article/news/biomarkers-to-combat-lung-cancer
Article - 23/03/2015 cytena GmbH facilitates the separation of single cells cytena GmbH, a start-up company which was spun out from the Department of Microscystems Engineering (IMTEK) at the University of Freiburg in 2014, has developed a device that enables single cells to be deposited safely and gently using a single-cell printer called cy-Clone. Once processed, the cells can be used to study tumour heterogeneity and to create clonal cell lines for producing antibodies. https://www.gesundheitsindustrie-bw.de/en/article/news/cytena-gmbh-facilitates-the-separation-of-single-cells
Dossier - 10/03/2014 Cancer therapy and cancer diagnostics Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics